Premature (before age 75 and 80) mortality has been declining in Australia, but there has been considerable variation in the rate of decline across diseases.
I. Introduction
Previous authors have argued that "reducing premature mortality is a crucial public health objective" (Renard, Tafforeau, and Deboosere (2014) ). A widely used measure of premature mortality is years of potential life lost (YPLL) before a given age (e.g. age 75), i.e. the number of years not lived by an individual who died before that age (Association of Public Health
Epidemiologists in Ontario (2015)). Statistics of YPLL are published by the World Health Organization, the OECD, and government agencies of the U.S., Switzerland, and other countries. Burnet et al (2005) argue that YPLL "should be considered when allocating research funds."
The premature (before age 75) mortality rate has been declining in Australia; it declined 24% between 1998 and 2011. 1 But as shown in Figure 1 , there has been considerable variation in the rate of decline across diseases. The figure displays data for the 10 diseases (ICD-10 blocks) with the largest average premature mortality rates. The premature mortality rates of three of these diseases declined by more than 40%, while the premature mortality rates of three other diseases declined by less than 10%.
In this paper, I will analyze the effect that pharmaceutical innovation had on premature mortality from all diseases in Australia during the period 1998-2011. 2 In essence, I will investigate whether the diseases that experienced more pharmaceutical innovation had larger declines in premature mortality. I will analyze the effect that pharmaceutical innovation had on hospital separations as well as on premature mortality from all diseases. Figure 3 shows that there was considerable variation across diseases in the 1998-2012 growth in the number of hospital separations. For example, the number of separations due to episodic and paroxysmal disorders (G40-G47)
increased by 89%, while the number of separations due to diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified (I80-I89) increased by 23%.
I will also analyze the effect that pharmaceutical innovation had on survival from all types of cancer during the period 1986-2007. Cancer is the leading cause of burden of disease in Australia, accounting for about one fifth of the total burden (AIHW (2010)). With 1 in 2
Australians developing cancer and 1 in 5 dying from it before the age of 85, cancer has a major impact on individuals, their families and the health-care system (AIHW (2012a)). In the cancer survival analysis, I will control for the number of people diagnosed (incidence) and the mean age at which they were diagnosed.
Figure 4 presents a summary of trends in 5-year survival rates, by cancer site, between the periods 1982-1987 and 2006-2010. 5 In general, survival from most cancers improved over time. However, the change in survival was not uniform over time and across cancer types. For example, survival from cervical cancer increased until the early 1990s but did not change significantly thereafter. By way of contrast, survival from cancer of unknown primary site remained virtually unchanged until the 2000s when it more than doubled. The cancers that showed the greatest percentage-point increase in survival were: prostate cancer, kidney cancer, and non-Hodgkin lymphoma. Five-year survival from these cancers increased by 24 percentage points or more in absolute terms. Other cancers that showed a greater proportional increase in survival included liver cancer, cancer of unknown primary site, and acute myeloid leukemia.
Five-year survival from these cancers more than doubled between the periods 1982-1987 and 2006-2010 , despite remaining lower than the average.
The analysis will be based on aggregate (longitudinal disease-level) data 6 rather than patient-level data. Stukel et al (2007) argue that comparisons of outcomes between patients treated and untreated in observational studies may be biased due to differences in patient 5 Source: AIHW Australian Cancer Database (2007) . Cancer survival and prevalence in Australia: period estimates from 1982 to 2010, Figure 3 .5 6 The premature mortality and hospital separations analyses will be based on data on about 170 diseases. The cancer survival analysis will be based on data on about 30 cancer sites.
prognosis between groups, often because of unobserved treatment selection biases. I believe that difference-in-differences estimates based on aggregate panel data are much less likely to be subject to unobserved treatment selection biases than estimates based on cross-sectional patientlevel data.
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In Section II, I describe econometric models of premature mortality, hospital separations, and cancer survival. The data sources used to construct the data to estimate these models are described in Section III. Empirical results are presented in Section IV. Key implications of the estimates are discussed in Section V. Section VI provides a summary and conclusions.
II.
Econometric models of premature mortality, hospital separations, and cancer survival
A. Premature mortality models
In his model of endogenous technological change, Romer (1990) hypothesized an aggregate production function such that an economy's output depends on the "stock of ideas" that have previously been developed, as well as on the economy's endowments of labor and capital. The premature mortality model that I will estimate may be considered a health production function, in which premature mortality is an inverse indicator of health output or outcomes, and the cumulative number of drugs approved is analogous to the stock of ideas. The first model will be of the following form:
where YPLL75it = years of potential life lost before age 75 from disease i in year t (t = 1998,…,2004, 2006,…,2011) 8 per 100,000 population below age 75 YPLL80it = years of potential life lost before age 80 from disease i in year t per 100,000 population below age 80 Inclusion of year and disease fixed effects controls for the overall decline in premature mortality and for stable between-disease differences in premature mortality. 9 Negative and significant estimates of βk in eqs.
(1) and (2) would signify that diseases for which there was more pharmaceutical innovation had larger declines in premature mortality. The functional form of eqs.
(1) and (2) has the property of diminishing marginal productivity: the absolute reduction in premature mortality declines with each successive increase in the number of drugs.
From estimates of eq. (1) and (2), there are two alternative, nearly equivalent, ways to determine how much of the decline in premature mortality during the sample period (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) can be attributed to the registration of new drugs. The first way is to compute βk * [mean (CUM_NCEi,2011 -k) -mean(CUM_NCEi,1998 ]. The second way is based on the year fixed effects. The expression (δ2011 -δ1998) indicates the 1998-2011 decline in premature mortality, controlling for (holding constant) the number of drugs, i.e., in the absence of pharmaceutical innovation. Suppose eq. (1) is estimated, excluding CUM_NCEi,t-k, and that the year fixed effects from that equation are denoted by δ't. Then (δ'2011 -δ'1998) indicates the 1998-2011 decline in premature mortality, not holding constant the number of drugs, i.e., in the presence of pharmaceutical innovation, and (δ'2011 -δ'1998) -(δ2011 -δ1998) is an estimate of the 1998-2011 decline in premature mortality attributable to pharmaceutical innovation. 9 The year fixed effects also control for population growth.
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The data exhibit heteroskedasticity: diseases with larger total premature mortality during 1998-2011 had smaller (positive and negative) annual percentage fluctuations in YPLL75 and YPLL80. Eqs.
(1) and (2) will therefore be estimated by weighted least-squares, weighting by the mean premature mortality rate during 1998-2011 (e.g. (Σt YPLL75it) / 13). The standard errors of eq. (1) and (2) will be clustered within diseases.
The measure of pharmaceutical innovation in eqs.
(1) and (2)-the number of chemical substances previously registered to treat a disease-is not the theoretically ideal measure.
Premature mortality is presumably more strongly related to the drugs actually used to treat a disease than it is to the drugs that could be used to treat the disease. A preferable measure is the are not available for Australia. But failure to control for non-pharmaceutical medical innovation is unlikely to bias estimates of the effect of pharmaceutical innovation on premature mortality, for two reasons. First, more than half of U.S. funding for biomedical research came from pharmaceutical and biotechnology firms (Dorsey et al (2010) ). Much of the rest came from the federal government (i.e. the NIH), and new drugs often build on upstream government research (Sampat and Lichtenberg (2011) ). The National Cancer Institute (2015b) says that it "has played an active role in the development of drugs for cancer treatment for 50 years… [and] that approximately one half of the chemotherapeutic drugs currently used by oncologists for cancer treatment were discovered and/or developed" at the National Cancer Institute.
Second, previous research based on U.S. data indicates that non-pharmaceutical medical innovation is not positively correlated across diseases with pharmaceutical innovation. Lichtenberg (2014a) showed that, in the U.S. during the period 1997-2007, the rate of pharmaceutical innovation was not positively correlated across diseases with the rate of medical procedure innovation and may have been negatively correlated with the rate of diagnostic imaging innovation. Also, Lichtenberg (2014b) found that estimates of the effect of pharmaceutical innovation on U.S. cancer mortality rates were insensitive to the inclusion or exclusion of measures of non-pharmaceutical medical innovation. This suggests that failure to control for other medical innovation is unlikely to result in overestimation of the effect of pharmaceutical innovation on longevity growth.
In eqs. (1) and (2) estimated eq. (3). Estimates of the "relative utilization index," based on data on molecules that were first listed on the PBS after 1991, are shown in Figure 5 . These estimates indicate that it takes about 9 years for a molecule to attain its peak level of utilization. The number of prescriptions 9 years after first PBS listing is about 2.6 times as great as the number of prescriptions one year after first PBS listing. Moreover, Figure 5 provides a conservative estimate of the slope of the age-utilization profile, because there was zero utilization of some molecules in the first few years after they were first listed.
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The effect of a drug's PBS listing on premature mortality is likely to depend on both the quality and the quantity of the drug. Indeed, it is likely to depend on the interaction between quality and quantity: a quality improvement will have a greater impact on mortality if drug utilization (quantity) is high. Although newer drugs tend to be of higher quality than older drugs (see Lichtenberg (2014c) ), the relative quantity of very new drugs is quite low, so the impact on mortality of very new drugs is lower than the impact of older drugs. 
B. Hospital separations model
The hospital separations model I will estimate is:
where N_HOSPit = the number of hospital separations due to disease i in year t (t = 1998,…,2011)
The hospital separations data also exhibit heteroskedasticity: diseases with larger mean hospital separations during 1998-2011 had smaller (positive and negative) annual percentage fluctuations in N_HOSP. Eq. (4) will therefore be estimated by weighted least-squares, weighting by the mean number of hospital separations during 1998-2011 ((Σt N_HOSPit) / 14).
The standard errors of eq. (4) will be clustered within diseases.
C. Cancer survival model
Now I will describe how I will analyze the effect that pharmaceutical innovation had on survival from all types of cancer during the period 1986-2007. The survival measure I will use is the 5-year relative survival rate. Five-year survival reflects the probability of being alive for at least five years after cancer diagnosis. It is a standard indicator used in reporting to reflect the prognosis of cancer and to compare survival across different cancers, time periods and groups of people.
Relative survival is the standard approach for measuring population-based cancer survival (Coleman et al. (2011) ). It is calculated from two measures of crude survival: observed and expected survival. Observed survival refers to the proportion of people alive for a given amount of time after a diagnosis of cancer and is calculated from population-based cancer data.
Expected survival refers to the proportion of people in the general population alive for a given amount of time and is calculated from life tables of the entire Australian population, assumed to be cancer-free. Relative survival is calculated from observed survival divided by expected survival, where the numerator and denominator have been matched for sex, age, calendar year, and where applicable, remoteness and socioeconomic status.
One of the advantages of relative survival is that it does not require information on the cause of death. By adjusting the survival of individuals with cancer for the underlying mortality that they would have experienced in the general population, relative survival reflects the net survival associated with cancer. In other words, relative survival is an inverse measure of the excess mortality attributed, either directly or indirectly, to a diagnosis of cancer.
The relative survival data I will analyze were calculated using the period method (Brenner & Gefeller (1996) ). The period method calculates survival from a given follow-up or at-risk time period. Survival estimates are based on the survival experience of people who were diagnosed before or during this period, and who were at risk of dying during this period. Because the period method allows recent years of follow-up to be selected, it produces up-to-date survival estimates that reflect recent changes in cancer survival trends (Brenner (2002) ; Brenner & Hakulinen (2002a , 2002b ). The period method is an alternative to the traditional cohort method, which focuses on a group of people diagnosed with cancer in a past time period, and follows these people over time.
The U.S. National Cancer Institute (2015a) says that "certain factors may cause survival times to look like they are getting better when they are not. These factors include lead-time bias and overdiagnosis."
Lead-time bias. Survival time for cancer patients is usually measured from the day the cancer is diagnosed until the day they die. Patients are often diagnosed after they have signs and symptoms of cancer. If a screening test leads to a diagnosis before a patient has any symptoms, the patient's survival time is increased because the date of diagnosis is earlier. This increase in survival time makes it seem as though screened patients are living longer when that may not be happening. This is called lead-time bias. It could be that the only reason the survival time appears to be longer is that the date of diagnosis is earlier for the screened patients. But the screened patients may die at the same time they would have without the screening test. Over-diagnosis. Sometimes, screening tests find cancers that don't matter because they would have gone away on their own or never caused any symptoms. These cancers would never have been found if not for the screening test. Finding these cancers is called overdiagnosis. Over-diagnosis can make it seem like more people are surviving cancer longer, but in reality, these are people who would not have died from cancer anyway.
To guard against the risk that lead-time bias and over-diagnosis could bias my estimates of the effect of pharmaceutical innovation on cancer survival, I will control for (changes in) the number of people diagnosed (incidence) and the mean age at which they were diagnosed.
The cancer survival model I will estimate is:
where ODDSst = RELSURV5st / (1 -RELSURV5st) RELSURV5st = the 5-year relative survival rate from cancer at site s in year t (t = 1986,…,2007) CUM_NCEs,t-k = ∑d INDds LISTED_PBSd,t-k = the number of new chemical entities (drugs) to treat cancer at site s that had been listed on the PBS by the end of year t-k AGE_DIAGst = the mean age at which patients were diagnosed with cancer at site s in year t N_CASESst = the number of patients diagnosed with cancer at site s in year t
Eq. (5) will be estimated by weighted least-squares, weighting by N_CASESst. The standard errors will be clustered within cancer sites. and 80, by disease and year (1998-2004 and 2006-2011) , and population by age and year were constructed from the WHO Mortality Database (World Health Organization (2015b)). (2015)).
III. Data sources

IV. Empirical results
A. Premature mortality model estimates
Estimates of CUM_NCE coefficients from models of premature mortality caused by all diseases (eqs. (1) and (2)) are presented in Panels A and B of Table 1 . Panel A shows estimates of eq. (1), where the dependent variable is the log of years of potential life lost before age 75 per 100,000 people below age 75. Models are estimated for 6 alternative assumed values of the lag (in years) from the number of drugs ever listed on the PBS to premature mortality: k = 0, 3, 6, 9, 12, 15. As shown in lines 1 and 2, the estimates of β0 and β3 are not statistically significant. 20 Many drug databases contain information about drug indications, but this information is usually in text form only. 21 Mortality data are reported in 5-year age groups. I assume that deaths in a 5-year age group occur at the midpoint of the age group. For example, I assume that deaths at age 35-39 years occurred at age 37.5. The Association of Public Health Epidemiologists in Ontario (2015) uses this method.
However, as shown in lines 3 and 4, the estimates of β6 and β9 are negative and statistically significant (p-value < .04). This signifies that the number of life-years lost before age 75 is inversely related to the number of drugs that had been listed on the PBS up until 6-9 years earlier. Since, as shown in Figure 5 , drugs are used much less frequently during the first few years after they are first listed on the PBS than they are later on, it is not surprising that it takes 6-9 years for the addition of new drugs to the PBS formulary to have a significant negative effect on premature mortality. The insignificance of β12 and β15 may be due to the fact that newer drugs (e.g. drugs listed 9 years earlier) are of higher quality than older drugs (e.g. drugs listed 15 years earlier).
Panel B shows estimates of eq. (2), where the dependent variable is the log of years of potential life lost before age 80 per 100,000 people below age 80. Once again, the estimates of β0 and β3 are not statistically significant (p-value > .05), although the estimate of β3 is nearly significant (p-value = .056). As shown in lines 9-11 of Table 1 , the estimates of β6, β9, and β12
are all negative and statistically significant: the number of life-years lost before age 80 is inversely related to the number of drugs that had been listed on the PBS up until 6-12 years earlier.
As discussed above, the reduction in premature mortality attributable to previous pharmaceutical innovation can be estimated by comparing the year fixed effects from a model including a CUM_NCE measure to the year fixed effects from a similar model that excludes the CUM_NCE measure. I have done this for the model shown in line 4 of Table 1 : ln(YPLL75it) = β9 CUM_NCEi,t-9 + αi + δt + εi,t. 22 (Mortality before ages 75 and 80 are both most strongly inversely related to the number of drugs ever listed 9 years earlier.) The calculations are depicted in Figure 6 . In 1998, the number of potential years of life lost before age 75 per 1,000 population under age 75 years was 54.7 (Source: AIHW (2015c), Table S3 ). Between 1998 and 2011, the premature (before age 75) mortality rate declined by 11.7, to 43.0. 23 The estimates indicate that if no new drugs had been listed on the PBS during 1989-2002, the premature 22 Estimates of parameters of models of ln(YPLL75it) and ln(YPLL80it) including and excluding CUM_NCEi,t-9 are shown in Appendix Table 2 . 23 Since eq. (1) includes fixed disease effects, this decline controls for changes in the distribution of deaths, by cause. When changes in the distribution of deaths, by cause, are not controlled for, the decline is slightly greater, from 54.7 to 41.6. mortality rate would have declined by only 4.7, from 54.7 to 50.0. Hence 60% (= 1 -(4.7 / 11.7)) of the decline in premature mortality was due to previous pharmaceutical innovation.
The effects on premature mortality of both the number of drugs and the number of chemical subgroups (drug classes) for the disease ever listed 9 years earlier are investigated in Table 2 . Six models are presented in the table. The dependent variable in the first 3 models (lines 4, 4a, and 4b) is the log of the premature (before age 75) mortality rate. The model in line 4 of Table 2 is identical to the model in line 4 of Table 1 : the only regressor (aside from disease and year fixed effects) is CUM_NCEi,t-9. In line 4a, the only regressor is CUM_SUBGROUPi,t-9.
The coefficient on this variable is insignificant. The model in line 4b includes both CUM_NCEi,t-9 and CUM_SUBGROUPi,t-9. Only the coefficient on CUM_NCEi,t-9 is significant.
The dependent variable in the last 3 models (lines 10, 10a, and 10b) is the log of the premature (before age 80) mortality rate. The model in line 10 of Table 2 is identical to the model in line 10 of Table 1 . In line 10a, the only regressor is CUM_SUBGROUPi,t-9. The coefficient on this variable is insignificant. The estimates of the first 5 models in Table 2 support the hypothesis that premature mortality depends only on the number of drugs ever listed on the PBS, not on the number of drug classes. This would be the case if drugs within the same class are not "therapeutically equivalent." 24 In the model in line 10b, the coefficient on CUM_NCEi,t-9 is negative and significant, and the coefficient on CUM_SUBGROUPi,t-9 is positive and significant. High collinearity between these two variables may account for this. Moreover, the net effect of growth of the number of drugs and the number of drug classes is to reduce premature mortality.
B. Hospital separations model estimates
Estimates of CUM_NCE coefficients from models of hospital separations caused by all diseases (eq. (4)) are presented in Table 3 . As shown in line 13, the number of hospital separations in year t is not significantly related to the number of drugs ever listed on the PBS in year t. However, as shown in lines 14-18, the number of hospital separations is significantly inversely related to the number of drugs ever listed on the PBS 3-15 years earlier. The number 24 Drugs are considered to be therapeutically equivalent if they have essentially the same effect in the treatment of a disease or condition. http://medical-dictionary.thefreedictionary.com/therapeutic+equivalent of hospital separations is most strongly inversely related to the number of drugs ever listed on the PBS 12 years earlier. The reduction in hospital separations attributable to previous pharmaceutical innovation can be estimated by comparing the year fixed effects from a model including a CUM_NCE measure to the year fixed effects from a similar model that excludes the CUM_NCE measure. I have done this for the model shown in line 17 of Table 3 : ln(N_HOSPit) = β12 CUM_NCEi,t-12 + αi + δt + εi,t. 25 The results are displayed in Figure 7 . Between 1998 and 2011, the number of hospital separations increased by 47%, from 5.7 million to 8.4 million.
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(The population of Australia increased by 21% during this period.) The estimates indicate that if no new drugs had been listed on the PBS during 1986-1999, the number of hospital separations would have increased by 66%, from 5.7 million to 9.5 million. The number of hospital separations in 2011 would have been 12.6% higher: 1.06 million additional separations.
C. Cancer survival model estimates
Estimates of CUM_NCE coefficients from models of cancer survival (eq. (5)) are presented in Table 4 . AGE_DIAGst and ln(N_CASESst) were included as covariates in all models. For simplicity, the coefficients on these variables are not shown in Table 4 ; both of them were highly significant and had the expected signs, and were very similar for different values of k. For example, when k=9, the coefficient on AGE_DIAGst is -0.0954 (std. err. = .0199; Z = 4.80), and the coefficient on ln(N_CASESst) is 0.6123 (std. err. = .1488; Z = 4.11).
Thus reductions in mean age at diagnosis and increases in the number of patients diagnosed are associated with increases in survival rates.
As shown in lines 19-23, the cancer survival rate is significantly positively related to the number of drugs that had ever been listed on the PBS 0-12 years earlier, controlling for mean age at diagnosis and the number of patients diagnosed. The cancer survival rate is most strongly positively related to the number of drugs that had ever been listed on the PBS 9 years earlier. 25 Estimates of parameters of models of ln(N_HOSPit) including and excluding CUM_NCEi,t-12 are shown in Appendix Table 3 . 26 Since eq. (4) includes fixed disease effects, this increase controls for changes in the distribution of separations, by principal diagnosis. When changes in the distribution of separations, by principal diagnosis, are not controlled for, the increase is greater, from 5.7 million to 9.3 million.
The increase in the cancer survival rate attributable to previous pharmaceutical innovation can be estimated by comparing the year fixed effects from a model including a CUM_NCE measure to the year fixed effects from a similar model that excludes the CUM_NCE measure. I have done this for the model shown in line 22 of Table 4 : ln(ODDSst) = β9 CUM_NCEs,t-9 + π AGE_DIAGst + γ ln(N_CASESst) + αs + δt + εst. 27 The results are displayed in Figure 8 . 28 
V. Discussion
Now I will use the estimates of eqs. (1), (2), and (4) to calculate the number of life-years gained in 2011 from previous pharmaceutical innovation and medical expenditure per life-year gained. The calculations are summarized in Table 5 . According to AIHW (2015c , Table S3 ), 870,672 years of potential life were lost before age 75 in 2011. 30 The difference between the two estimates of the 1998 year fixed effect in line 2 of Appendix 27 Estimates of parameters of models of ln(ODDSst) including and excluding CUM_NCEs,t-9 are shown in Appendix Table 4 . 28 Since the dependent variable in eq. (5) higher. I will assume that hospital expenditure in 2011 would also have been 13.1% higher.
Total expenditure on public hospital services and private hospitals in 2011 was $AUS 52,220 million (AIHW (2014), Table A1 ). 32 This is just over half (52%) of the total cost (government and patient contribution) of PBS drugs in 2011 ($AUS 11,145) reported in ASM. The latter figure is 8.6% higher than the figure for total pharmaceutical sales reported in the OECD Health database ($AUS 10,261), which is surprising since, as noted earlier, the PBS does not assume responsibility for the cost of drugs to patients while they are in the hospital. 
VI. Summary and conclusions
Premature (before age 75 and 80) mortality has been declining in Australia, but there has been considerable variation in the rate of decline across diseases. I first analyzed the effect that 35 A previous study (Lichtenberg (2014c) ) found that pharmaceutical innovation was cost-saving in the U.S. In that study, the measure of pharmaceutical innovation was the mean vintage of drugs. An instrument for pharmaceutical innovation--the potential size of the market for drugs for a medical condition-was used. The value of the benefits of pharmaceutical innovation (primarily reduction in hospital expenditure and work-loss days) implied by the IV estimates was about 30 percent larger than the value implied by the OLS estimates.
36 Lichtenberg (2009) demonstrated that the number of QALYs gained from pharmaceutical innovation could be either greater than or less than the number of life-years gained.
pharmaceutical innovation had on premature mortality from all diseases in Australia during the period 1998-2011 by investigating whether the diseases that experienced more pharmaceutical innovation had larger declines in premature mortality. My estimates indicated that 60% of the 1998-2011 decline in premature (before age 75) mortality was due to previous pharmaceutical innovation. The estimates generally supported the hypothesis that premature mortality depends on the number of drugs ever listed on the PBS, not on the number of drug classes. This would be the case if drugs within the same class are not "therapeutically equivalent." 4 Survival trends, 1982 4 Survival trends, -1987 4 Survival trends, to 2006 4 Survival trends, -2010 Arrow positions indicate survival estimates and arrow lengths indicate the change in survival between the period 1982-1987 and 2006-2010 . Cancers labeled with an asterisk (*) indicate changes that were not statistically significant. Data for 1988 Data for -1993 Data for , instead of 1982 Data for -1987 The premature mortality rate is the number of years of potential life lost before age 75 per 1,000 population under age 75 years. Table 1 Estimates of CUM_NCE coefficients from premature mortality equations (eqs. (1) and (2)) A. Eq. (1):
Each estimate is from a different model. Estimates in bold are statistically significant (p-value < .05). N = 1788. All models include 170 fixed disease effects and 13 fixed year effects. Models were estimated via weighted least-squares. Weight used in lines 1-6 was ( t YPLL75 it ) / 13); weight used in lines 7-12 was ( t YPLL80 it ) / 13). Standard errors were clustered within diseases. Table 3 Estimates of CUM_NCE coefficients from hospital separations equation (eq. (4)): Appendix Table 2 Estimates of parameters of premature mortality models including and excluding CUM_NCE i,t-9 CUM_NCE i,t-9 included CUM_NCE i,t-9 excluded A. Eq. (1): ln(YPLL75 it ) =  9 CUM_NCE i,t-9 +  i +  t +  i,t B. Eq. (2): ln(YPLL80 it ) =  9 CUM_NCE i,t-9 +  i +  t +  i,t 
